The lawsuit centers on allegations that Regeneron misled shareholders regarding the efficacy of Fianlimab combined with Libtayo. Throughout the class period, spanning August 1, 2025, to May 15, 2026, the company repeatedly characterized the drug combination as a high-potential blockbuster. Plaintiffs argue that management suppressed evidence that the study’s statistical assumptions were flawed and that the treatment failed to show meaningful improvement over existing therapies.
Regeneron Investors Face Deadline in Securities Class Action
September 14, 2026, marks the final opportunity for investors to seek lead plaintiff status in a securities class action lawsuit against Regeneron Pharmaceuticals. The litigation follows a sharp decline in share price triggered by the failure of a Phase 3 clinical trial involving a potential melanoma treatment.
Suspicion intensified in April 2026 when the company altered its trial protocol, citing slow event rates. While management initially suggested these delays indicated superior performance of the test arms, the company later conceded the changes were made months earlier to address regulatory concerns. On May 15, 2026, Regeneron confirmed the trial failed to reach its primary endpoint of progression-free survival, resulting in an $11 billion market capitalization loss. Reed Kathrein, a partner at Hagens Berman, stated the firm is investigating whether the company intentionally withheld these developments to maintain investor confidence despite knowing the treatment’s limited potential.
Comments (0)
No comments yet. Be the first!